Medical Diabetes Management Devices sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Medical Diabetes Management Devices
1.1 - About Medical Diabetes Management Devices sector
Companies in the Medical Diabetes Management Devices category design, manufacture, and integrate hardware and software that measure glucose and deliver insulin for people with diabetes. They provide continuous glucose monitoring, smart insulin delivery, and connected data platforms that support clinical decision-making and remote care. The value proposition centers on accuracy, reliability, interoperability, and insights that help providers and patients improve glycemic control while streamlining care workflows and supply management.
Typical offerings span continuous glucose monitoring sensors with wireless transmitters, insulin pumps and patch pumps, and automated insulin delivery or hybrid closed‑loop systems that pair CGM data with algorithmic dosing. Vendors also provide smart insulin pens, blood glucose meters with test strips, mobile companion apps, clinician dashboards, and cloud data services that integrate via Bluetooth and HL7/FHIR. Many support remote patient monitoring, device analytics, and compliance with FDA/CE standards and cybersecurity requirements.
Primary customer segments include hospitals and health systems, endocrinology and diabetes clinics, and home health providers, with payers increasingly involved in adoption and reimbursement. Outcomes typically include improved time-in-range and reduced hypoglycemia events, lower readmissions and total cost of care, expanded remote monitoring capacity, and better therapy adherence. Strategic buyers in diabetes devices seek platforms that enable data-driven care plans, interoperable workflows, and scalable patient support programs.
2. Buyers in the Medical Diabetes Management Devices sector
2.1 Top strategic acquirers of Medical Diabetes Management Devices companies
Tandem Diabetes Care
- Description: Provider of insulin delivery and diabetes technology solutions, manufacturing automated insulin delivery systems such as the Tandem Mobi and t:slim X2 pumps with Control-IQ hybrid closed-loop technology, and offering complementary diabetes education, pump training, software updates and benefit programs for effective blood-glucose management in multiple international markets.
- Key Products:
- Tandem Mobi system: Wearable, ultra-compact automated insulin delivery pump utilizing Control-IQ technology to continuously adjust basal insulin, providing personalized glucose control with minimal device footprint
- t: slim X2 insulin pump: Touchscreen insulin pump featuring Control-IQ hybrid closed-loop algorithm that automatically delivers and suspends insulin based on glucose sensor data to ease daily diabetes management
- t: connect Diabetes Management Application: Cloud-based app that syncs pump and glucose data, offering users and clinicians real-time dashboards and reports to monitor trends, adjust therapy, and improve outcomes
- t: simulator Insulin Pump Demo App: Mobile simulation app replicating the t:slim X2 pump interface, enabling prospective users and educators to practice programming and navigation without live insulin delivery.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Medical Diabetes Management Devices sector
M&A buyer group 1: Glucose Monitoring Devices
DarioHealth
- Type: N/A
- Employees: ●●●●●
- Description: Provider of data-driven digital health solutions for chronic condition management, offering an integrated platform of connected devices, mobile apps and analytics for diabetes, hypertension, weight, behavioral and musculoskeletal care, as well as employer and health-plan programs that improve outcomes and lower costs.
- Key Products:
- Diabetes Management Solution: Smartphone-connected digital therapeutic combining real-time glucose monitoring, personalized coaching, and evidence-based interventions to drive sustained behavior change and improved glycemic control
- Hypertension Management Solution: AI-driven program that pairs connected blood-pressure monitoring with adaptive software and coaching to help users track readings, receive feedback, and lower blood-pressure levels
- Cardiometabolic Suite for Employers: Multi-condition platform offered to employer populations, bundling diabetes, hypertension and related chronic-care programs to generate recurring outcomes-based revenue
- Multi-Condition Digital Therapeutics Platform: Core software infrastructure integrating life-science, behavioral-science and analytics capabilities to rapidly expand into additional chronic conditions and geographic markets.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Medical Diabetes Management Devices sector
3.1 - Buyout funds in the Medical Diabetes Management Devices sector
2.2 - Strategic buyer groups for Medical Diabetes Management Devices sector
4 - Top valuation comps for Medical Diabetes Management Devices companies
4.2 - Public trading comparable groups for Medical Diabetes Management Devices sector
Valuation benchmark group 1: Diabetes Care Device Companies
Medtronic
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of medical technology solutions including advanced devices and therapies for various medical conditions, focusing on cardiac care, neurological disorders, diabetes management, and surgical innovations to improve patient outcomes and enhance healthcare delivery.
- Key Products:
- Cardiac devices: Pacemakers and defibrillators for heart rhythm disorders
- Insulin pumps: Advanced systems for diabetes management
- Surgical innovations: Minimally invasive surgical tools and robotics
- Neurostimulation: Implants for pain management and neurological conditions
- Patient monitoring: Advanced monitoring systems for acute care.